ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Attempting TFR is currently recommended for chronic phase (CP) CML patients on TKI treatment for at least 3 years, with a sustained DMR for at least 2 years and without evidence of any ABL kinase domain mutation (Atallah and Sweet, 2021; Pavlovsky et al., 2021).